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major	role	in	proliferative	signalling	in	a	variety	of	cancers	(Baselga & Swain, 2009; 60	










(Tykerb/Tyverb)	have	been	successful	in	the	clinic	(Blackwell et al., 2010; D. Cameron et 70	
al., 2017; Dieras et al., 2017; Geyer et al., 2006; Krop et al., 2017; Swain et al., 71	
2015; Verma et al., 2012).	72	
	 While	HER2	itself	has	no	known	ligand,	HER3	binds	the	growth	factor	neuregulin	73	
(NRG,	also	known	as	heregulin	or	HRG)	to	induce	heterodimerisation	and	signalling	74	
(Sliwkowski et al., 1994).	HER3	has	been	implicated	in	therapeutic	resistance	to	HER2-75	
targeted	therapy	through	a	variety	of	mechanisms,	including	receptor	rephosphorylation,	76	
HER3	overexpression	and	increased	NRG	production	(reviewed	in	(Claus, Patel, Ng, & 77	
Parker, 2014)).	In	terms	of	cellular	signalling	in	response	to	HER-family	kinase	inhibition,	78	
HER3-mediated	buffering	through	the	Akt/PKB	signalling	axis	has	been	shown	to	be	an	79	




receptors	have	bound	ligand,	although	singly-bound	dimers	can	also	occur		(Garrett et al., 84	
2002; P. Liu et al., 2012; Ogiso et al., 2002).	Although	HER2	has	no	known	ligand,	it	85	
natively	adopts	this	upright,	dimerisation-ready	ectodomain	conformation	(Garrett et al., 86	
2002).	On	the	intracellular	side,	formation	of	the	active	kinase	domain	dimer	is	critically	87	
affected	by	the	conformation	of	the	juxtamembrane	domain	(JMD	(Jura, Endres, Engel, 88	
Deindl, Das, Lamers, et al., 2009a; Thiel & Carpenter, 2007).	The	kinase	domains	89	
associate	in	an	asymmetric	dimer,	which	resembles	the	CDK/cyclin-like	asymmetric	dimer	90	





electron	microscopy	(Mi et al., 2011).	Of	note	in	these	receptor	dimer	formations	was	the	95	
lack	of	active,	asymmetrical	kinase	domain	interactions	when	the	receptor	was	bound	to	the	96	
ATP-competitive	inhibitor	lapatinib	(Mi et al., 2011).	Although	these	interactions	have	97	
mainly	been	described	in	the	context	of	EGFR	homodimerisation,	they	remain	a	template	98	
for	the	interactions	of	the	rest	of	the	EGFR	family.	The	conformation	of	the	active	kinase	99	
domain	interaction	has	been	validated	for	EGFR-HER3	and	HER2-HER3	(Jura, Shan, Cao, 100	
Shaw, & Kuriyan, 2009b; Littlefield et al., 2014; van Lengerich, Agnew, Puchner, 101	





Clayton, Tavarnesi, & Johns, 2007; Y. Huang et al., 2016; Nagy, Claus, Jovin, & 107	
Arndt-Jovin, 2010; Needham et al., 2016; Saffarian, Li, Elson, & Pike, 2008; van 108	








occur	and	priming	sites	to	be	stably	phosphorylated	(A. J. M. Cameron, Escribano, 117	
Saurin, Kostelecky, & Parker, 2009).	Similar	effects	have	been	observed	in	several	118	
additional	kinases,	including	PKB/Akt,	IRE1,	and	AMPK	(Okuzumi et al., 2009; Papa, 119	
Zhang, Shokat, & Walter, 2003; Ross et al., 2017; Wang et al., 2012).		120	
A	notable	example	of	nucleotide	binding	pocket	occupation	inducing	behaviour	121	
independent	of	catalysis	has	been	described	for	the	RAF	family,	originally	in	cRAF,	where	the	122	





(Hatzivassiliou et al., 2010; Mckay, Ritt, & Morrison, 2011; Poulikakos, Zhang, 127	
Bollag, Shokat, & Rosen, 2010; Thevakumaran et al., 2014).	Within	the	EGFR	family,	128	
we	and	others	have	shown	previously	that	quinazoline	inhibitors	can	cause	homodimer	129	
formation	of	EGFR,	and	EGFR-MET	heterodimerisation,	by	stabilising	particular	kinase	130	
domain	conformers	(Arteaga, Ramsey, Shawver, & Guyer, 1997; Bublil et al., 2010; 131	





residues	involved	in	ATP-binding	(Boudeau, Miranda-Saavedra, Barton, & Alessi, 2006; 137	
Claus, Cameron, & Parker, 2013).	And	in	vitro	analysis	of	the	pseudokinome	showed	that	138	




binding	to	sustain	a	heterotrimeric	complex	with	LKB	and	MO25	(Zeqiraj, Filippi, Deak, 143	
Alessi, & van Aalten, 2009a; Zeqiraj et al., 2009b).	Similarly,	in	the	pseudokinase	144	
FAM20A	ATP-binding,	albeit	in	a	non-canonical	orientation,	is	essential	for	stabilising	the	145	
FAM20A/FAM20C	complex	(Cui et al., 2015; 2017).	ATP	binding	is	a	structural	146	
requirement	for	the	JAK2	JH2	V617F	mutant	to	promote	pathogenic	signalling	(Hammarén 147	
et al., 2015).	In	the	pseudokinase	MLKL,	ATP-binding	pocket	occupation	is	essential	for	148	
membrane	translocation	and	its	role	in	necroptotic	signalling	(Hildebrand et al., 2014; 149	
Murphy et al., 2013).		150	
HER3	is	able	to	bind	ATP	(crystallised	as	PDB	ID	3XKK,	3LMG),	as	well	as	the	Src/ABL	151	
inhibitor	Bosutinib	(PDB	ID	4OTW)	(Boxer & Levinson, 2013; Davis et al., 2011; Jura, 152	
Shan, Cao, Shaw, & Kuriyan, 2009b; Murphy et al., 2014; Shi, Telesco, Liu, 153	




























inhibitors	can	be	counter-acted	by	the	addition	of	growth	factors	(Wilson et al., 2012).	181	
This	includes	the	case	of	lapatinib-treated	HER2+	breast	cancer	cell	lines,	where	NRG	is	seen	182	
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Figure 1-figure supplement 2
b
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bind	strongly	to	HER3	but	not	to	other	EGFR	family	members	(Boxer & Levinson, 2013; 291	
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Figure 2-figure supplement 1
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Figure 2-figure supplement 2
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homodimerisation,	and	similar	to	the	Cyclin/CDK	binding	mode	(Jeffrey et al., 1995; X. 442	
Zhang et al., 2006),	this	canonical	active	dimerisation	interface	has	been	reported	across	443	
the	EGFR	family	including	the	heterodimerisation	of	HER3,	which	can	only	perform	the	444	
activator	role	(Jura, Shan, Cao, Shaw, & Kuriyan, 2009b; Littlefield et al., 2014; van 445	
































































normally	observed	in	active	kinase	domain	structures	(Huse & Kuriyan, 2002).	The	HER3	506	
ATP-bound	conformation	therefore	does	not	show	a	classical	active	conformation	with	the	507	






interaction	interfaces	have	been	observed	(Jura, Endres, Engel, Deindl, Das, Lamers, et 514	



































were	modelled	in	an	EGFR-like	symmetric	dimer	orientation	(Jura, Endres, Engel, Deindl, Das, 548	
Lamers, et al., 2009a).	Insert	highlights	the	interaction	interface.	The	schematic	representation	shows	549	
active	dimer	interface	residues	HER2I714	and	HER3V945,	as	well	as	the	two	residues	in	HER2	unique	to	this	550	
interface	for	further	mutational	analysis.	(b)	Lapatinib-bound	HER2		in	the	HER3-like	head-to-head	symmetric	551	






























































































(Eyers et al., 1998; Hatzivassiliou et al., 2010; Mckay et al., 2011; Poulikakos et al., 638	
















































intermittently	at	high	dose	(Amin et al., 2010).	Increased	production	of	growth	factors	685	
(including	NRG)	is	a	well-described	resistance	mechanism	against	HER2-targeted	therapy	686	
(reviewed	in(Claus et al., 2014)).	NRG	production	by	the	microenvironment	has	also	been	687	
shown	to	play	a	role	in	metastatic	spread	of	ovarian	cancer	cells	that	express	high	levels	of	688	
HER3	(Pradeep et al., 2014).	High	expression	levels	of	NRG	in	HER2+	breast	cancer	patients	689	
showed	a	strong	correlation	with	disease	recurrence	(Xia et al., 2013).	Several	somatic	690	
mutations	in	HER3	observed	in	cancer	fall	within	the	extracellular	domain	and	have	a	691	

































































by	FLIM	has	been	previously	described	(Barber et al., 2009; Parsons & Ng, 2002).	FLIM	755	
was	performed	using	time-correlated	single-photon	counting	(TCSPC)	with	a	multiphoton	756	












crystal	structure	of	the	active	EGFR	kinase	domain	(PDB	ID	2GS2)(X. Zhang et al., 2006)	769	
and	one	chain	of	the	crystal	structure	of	the	HER3	homodimer	(PDB	ID	3KEX)(Jura, Shan, 770	
Cao, Shaw, & Kuriyan, 2009b)	as	templates.	To	build	the	EGFR-like,	inactive,	symmetric	771	
dimer	we	have	used	the	crystal	structure	of	the	EGFR	homodimer	(PDB	ID	3GT8)(Jura, 772	
Endres, Engel, Deindl, Das, Lamers, et al., 2009a),	the	crystal	structure	of	EGFR	773	
complexed	with	lapatinib	(PDB	ID	1XKK)(Wood et al., 2004)	and	only	one	chain	of	the	774	
crystal	structure	of	the	HER3	homodimer	(PDB	ID	3KEX)(Jura, Shan, Cao, Shaw, & 775	
	 35	
Kuriyan, 2009b).	To	build	the	HER3-like	dimer	we	have	used	the	HER3	homodimer	776	
structure	(PDB	ID	3KEX)(Jura, Shan, Cao, Shaw, & Kuriyan, 2009b),	the	crystal	structure	777	
of	EGFR	lapatinib-bound	(PDB	ID	1XKK)(Wood et al., 2004)	and	the	crystal	structure	of	the	778	
inactive	EGFR	AMP-PNP	bound	(PDB	ID	2GS7)(X. Zhang et al., 2006).	The	sequence	779	
alignment	used	to	build	the	model	has	been	created	by	using	PRALINE	with	the	homology-780	
extended	alignment	strategy	(Simossis, 2005).	We	generated	200	three-dimensional	781	






package(Humphrey, Dalke, & Schulten, 1996),	and	measurement	of	interaction	surface	788	


























Delanchy et al., 2015)	814	
	815	
The	clustering	algorithm	expects	the	background	and	clusters	to	be	uniformly	distributed	816	
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